This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Intellipharmaceutics NASDAQ Update And Corporate Matters

TORONTO, Nov. 2, 2010 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and proposed manufacture of novel or generic controlled release and targeted release oral solid dosage drugs, today announced that the Company received a letter on October 29, 2010 from NASDAQ, stating that Intellipharmaceutics is not in compliance with NASDAQ's 'minimum stockholders' equity' continued listing requirement of $2.5 million under NASDAQ Listing Rule 5550(b)(1). As of August 31, 2010, Intellipharmaceutics' stockholders' equity was approximately $1.8 million. 

The notice has no immediate effect on the listing of Intellipharmaceutics' common stock on NASDAQ Capital Market ("the NASDAQ"), and its common stock will continue to trade on the NASDAQ under the symbol "IPCI" pending any further action taken by NASDAQ as described below. The notice will not affect the listing of the common stock on the Toronto Stock Exchange ("TSX"), which continues to trade under the symbol "I" in ongoing compliance with TSX listing conditions.

In accordance with NASDAQ Listing Rules, Intellipharmaceutics has 45 calendar days, or until December 13, 2010 to  submit to NASDAQ a plan of compliance detailing the actions Intellipharmaceutics has taken, or plans to take, that would bring it into compliance with this stockholders' equity requirement.  If the Company submits its plan and the plan is accepted, NASDAQ can grant an extension of up to 180 calendar days from October 29, 2010 for the Company to evidence compliance. Alternatively, Intellipharmaceutics could return to compliance if it satisfies the $35.0 million minimum for the 'market value of listed securities' continued listing requirement which is one of the alternatives to the 'minimum stockholders' equity' continued listing requirement under Rule 5550(b). 

If Intellipharmaceutics submits a plan of compliance and NASDAQ does not accept the Company's plan and does not meet the alternate continued listing requirement under Rule 5550(b), NASDAQ may then initiate delisting proceedings from NASDAQ, at which time Intellipharmaceutics may appeal NASDAQ's determination to a Listing Qualifications Panel. In the event of an appeal, the Company's common stock would remain listed on the NASDAQ Capital Market pending a decision by the Panel following the hearing. 

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.00 -0.02%
FB $100.22 -3.70%
GOOG $674.53 -1.30%
TSLA $152.07 -6.50%
YHOO $27.16 -2.90%


Chart of I:DJI
DOW 15,888.47 -316.50 -1.95%
S&P 500 1,845.20 -34.85 -1.85%
NASDAQ 4,273.0060 -90.1380 -2.07%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs